Donanemab (LY3002813), Eli Lilly’s experimental antibody-based immunotherapy, slowed cognitive and functional decline in patients at the earlier stages of Alzheimer’s disease, according to data from a Phase 2 trial. Findings from this trial, called TRAILBLAZER-ALZ (NCT03367403), also showed donanemab had a favorable safety profile, which was consistent with observations from previous clinical trials. “We are extremely pleased about these positive findings for donanemab as a potential therapy for people living with Alzheimer’s disease, the only…
You must be logged in to read/download the full post.
The post Donanemab Found to Slow Cognitive, Functional Decline in Early Alzheimer’s appeared first on BioNewsFeeds.